Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis - Poll - MDSpire

Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis

  • By

  • Zechang Xin

  • Xiaoyu Zhu

  • Hui Qu

  • Xing Ai

  • Kaixuan Wang

  • Xinyue Li

  • Ming Wang

  • Pisong Li

  • Zhongbin Han

  • Ningxin Qu

  • Weiting Yu

  • Hongshen Chen

  • June 10, 2026

  • 0 min

Share

Original Source(s)

Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis

  • by Zechang Xin, Xiaoyu Zhu, Hui Qu, Xing Ai, Kaixuan Wang, Xinyue Li, Ming Wang, Pisong Li, Zhongbin Han, Ningxin Qu, Weiting Yu, Hongshen Chen

  • June 10, 2026

Related Content

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib

Multimodal feature fusion model for breast mass malignant risk stratification

RSPO2-induced ferroptosis via PTBP1-mediated FSP1 mRNA decay suppresses breast cancer progression